Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;8(1):101-107.
doi: 10.21037/tau.2018.09.06.

Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer

Karl H Pang  1 , Aidan P Noon  2
Affiliations
Review

Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer

Karl H Pang et al. Transl Androl Urol. 2019 Feb.

Abstract

Bladder cancer (BC) is a common disease in both sexes and majority of cases present as non-muscle invasive BC (NMIBC). The percentage of NMIBC progressing to muscle invasive BC (MIBC) varies between 25% and 75% and currently there are no reliable molecular markers that may predict the outcome of high-risk (HR) NMIBC. Transurethral resection of the bladder tumour (TURBT) with intravesical bacillus Calmette-Guérin (BCG) or immediate radical cystectomy (RC) are the current gold standard treatment options. The European Association of Urology (EAU) guidelines recommend immediate or delayed RC for HR- and a subgroup of "highest-risk" NMIBC. These cases include pT1, carcinoma in-situ (CIS), multifocal disease, histological variants such as micropapillary and sarcomatoid, and patients who have contraindications to, or have failed with BCG. The comparative risks between maintenance BCG (mBCG) and immediate RC are unclear. However, RC may give patients the best oncological outcome.

Keywords: Immediate radical cystectomy; bladder cancer; non-muscle invasive bladder cancer (NMIBC); primary cystectomy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
    1. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295-300. 10.1007/s00345-009-0395-z - DOI - PMC - PubMed
    1. Moch H, Humphrey P, Ulbright T, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th edition. Lyon: IARCC Press, 2016. - PubMed
    1. Cumberbatch MG, Rota M, Catto JWF, et al. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016;70:458-66. 10.1016/j.eururo.2015.06.042 - DOI - PubMed
    1. Cumberbatch MG, Cox A, Teare D, et al. Contemporary Occupational Carcinogen Exposure and Bladder Cancer. JAMA Oncol 2015;1:1282. 10.1001/jamaoncol.2015.3209 - DOI - PubMed